PLATINOUS IODIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2I.Pt
Molecular Weight	448.893
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[I-].[I-].[Pt++]

InChI

InChIKey=ZXDJCKVQKCNWEI-UHFFFAOYSA-L

InChI=1S/2HI.Pt/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24435208https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdfftp://ftp.nrg.eu/pub/www/nrg/nrglib/2004/immobilisation_of_iodine.pdf
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039

There is no available sources on the medical use of platinum iodide. The salt is insoluble.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27736024	Crosslinking Agent 81

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Metastatic testicular tumors 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf	Primary	Approved 8429	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 1978
Metastatic ovarian tumors 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf	Primary	Approved 8429	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 1978
Advanced bladder cancer 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf	Primary	Approved 8429	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 1978
Non-small cell lung cancer 206 Sources: https://clinicaltrials.gov/ct2/show/NCT00686322	Primary	Phase IV 63	CISPLATIN Approved Use Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date 1978

PubMed

Title	Date	PubMed
Synthesis of tetracyclic chromenones via platinum(II) chloride catalysed cascade cyclization of enediyne-enones.	2014 Feb 28	24435208
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.	2017	28420003

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Name

Type

Language

PLATINOUS IODIDE

Common Name

English

PLATINUM DIIODIDE

Systematic Name

English

PLATINUM IODIDE (PTI2)

Common Name

English

PLATINOUS IODIDE [MI]

Common Name

English

PLATINUM(II) IODIDE

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID50999091